tiprankstipranks
Trending News
More News >
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
US Market

Allogene Therapeutics (ALLO) Stock Forecast & Price Target

Compare
1,440 Followers
See the Price Targets and Ratings of:

ALLO Analyst Ratings

Strong Buy
14Ratings
Strong Buy
11 Buy
3 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Allogene
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ALLO Stock 12 Month Forecast

Average Price Target

$7.77
▲(479.85%Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Allogene Therapeutics in the last 3 months. The average price target is $7.77 with a high forecast of $14.00 and a low forecast of $2.50. The average price target represents a 479.85% change from the last price of $1.34.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","15":"$15","3.75":"$3.75","7.5":"$7.5","11.25":"$11.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.77,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.77</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.75,7.5,11.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.27,2.249230769230769,3.2284615384615387,4.207692307692308,5.186923076923077,6.166153846153847,7.145384615384616,8.124615384615385,9.103846153846154,10.083076923076923,11.062307692307693,12.041538461538462,13.02076923076923,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.27,1.77,2.27,2.77,3.27,3.77,4.27,4.77,5.27,5.77,6.27,6.77,7.27,{"y":7.77,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.27,1.3646153846153846,1.4592307692307693,1.5538461538461539,1.6484615384615384,1.7430769230769232,1.8376923076923077,1.9323076923076923,2.026923076923077,2.121538461538462,2.216153846153846,2.310769230769231,2.4053846153846155,{"y":2.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.92,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.33,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.74,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.67,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.72,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.13,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$14.00Average Price Target$7.77Lowest Price Target$2.50
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ALLO
TipRanks AITipRanks
Not Ranked
TipRanks
$1.5
Hold
11.94%
Upside
Reiterated
06/07/25
The overall stock score is primarily influenced by significant financial challenges, including declining revenues and persistent losses. Technical indicators also suggest a bearish trend. While the earnings call provided some optimism with clinical trial advancements, operational delays and financial losses remain substantial hurdles.
Bernstein
$3$2.5
Hold
86.57%
Upside
Reiterated
06/05/25
Allogene Therapeutics (ALLO) Receives a Hold from Bernstein
Piper Sandler Analyst forecast on ALLO
Biren AminPiper Sandler
Piper Sandler
$7
Buy
422.39%
Upside
Reiterated
06/02/25
Allogene Therapeutics (ALLO) Receives a Buy from Piper Sandler
TD Cowen
Buy
Reiterated
06/02/25
Allogene Therapeutics (ALLO) Receives a Buy from TD Cowen
Canaccord Genuity Analyst forecast on ALLO
John NewmanCanaccord Genuity
Canaccord Genuity
$14
Buy
944.78%
Upside
Reiterated
06/02/25
Canaccord Genuity Reaffirms Their Buy Rating on Allogene Therapeutics (ALLO)
Citi
$4
Buy
198.51%
Upside
Reiterated
06/02/25
Citi Keeps Their Buy Rating on Allogene Therapeutics (ALLO)
H.C. Wainwright Analyst forecast on ALLO
Robert BurnsH.C. Wainwright
H.C. Wainwright
$8
Buy
497.01%
Upside
Reiterated
06/02/25
Promising Clinical Results and Strategic Initiatives Drive Buy Rating for Allogene Therapeutics
William Blair Analyst forecast on ALLO
Sami CorwinWilliam Blair
William Blair
Buy
Reiterated
05/14/25
Positive Outlook on Allogene Therapeutics Amid ALPHA3 Trial Delays and Market Expansion Potential
Oppenheimer Analyst forecast on ALLO
Matthew BieglerOppenheimer
Oppenheimer
$10$9
Buy
571.64%
Upside
Reiterated
05/14/25
Analysts Are Bullish on Top Healthcare Stocks: Allogene Therapeutics (ALLO), Biodesix (BDSX)
Truist Financial Analyst forecast on ALLO
Asthika GoonewardeneTruist Financial
Truist Financial
$14$10
Buy
646.27%
Upside
Reiterated
05/14/25
Citizens JMP Analyst forecast on ALLO
Reni BenjaminCitizens JMP
Citizens JMP
Hold
Downgraded
05/14/25
Allogene downgraded to Market Perform from Outperform at Citizens JMPAllogene downgraded to Market Perform from Outperform at Citizens JMP
Robert W. Baird Analyst forecast on ALLO
Jack AllenRobert W. Baird
Robert W. Baird
$12$9
Buy
571.64%
Upside
Reiterated
05/14/25
Allogene Therapeutics price target lowered to $9 from $12 at BairdAllogene Therapeutics price target lowered to $9 from $12 at Baird
Jefferies Analyst forecast on ALLO
Michael YeeJefferies
Jefferies
$8
Buy
497.01%
Upside
Reiterated
05/13/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: GlaxoSmithKline (LSE: GB:GSK), Sartorius Stedim Biotech (LSE: GB:0RG8) and Allogene Therapeutics (NASDAQ: ALLO)
RBC Capital Analyst forecast on ALLO
Luca IssiRBC Capital
RBC Capital
$10
Buy
646.27%
Upside
Reiterated
05/13/25
Allogene Therapeutics (ALLO) Gets a Buy from RBC Capital
Stifel Nicolaus Analyst forecast on ALLO
Benjamin BurnettStifel Nicolaus
Stifel Nicolaus
$4
Hold
198.51%
Upside
Reiterated
03/17/25
Stifel Nicolaus Keeps Their Hold Rating on Allogene Therapeutics (ALLO)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ALLO
TipRanks AITipRanks
Not Ranked
TipRanks
$1.5
Hold
11.94%
Upside
Reiterated
06/07/25
The overall stock score is primarily influenced by significant financial challenges, including declining revenues and persistent losses. Technical indicators also suggest a bearish trend. While the earnings call provided some optimism with clinical trial advancements, operational delays and financial losses remain substantial hurdles.
Bernstein
$3$2.5
Hold
86.57%
Upside
Reiterated
06/05/25
Allogene Therapeutics (ALLO) Receives a Hold from Bernstein
Piper Sandler Analyst forecast on ALLO
Biren AminPiper Sandler
Piper Sandler
$7
Buy
422.39%
Upside
Reiterated
06/02/25
Allogene Therapeutics (ALLO) Receives a Buy from Piper Sandler
TD Cowen
Buy
Reiterated
06/02/25
Allogene Therapeutics (ALLO) Receives a Buy from TD Cowen
Canaccord Genuity Analyst forecast on ALLO
John NewmanCanaccord Genuity
Canaccord Genuity
$14
Buy
944.78%
Upside
Reiterated
06/02/25
Canaccord Genuity Reaffirms Their Buy Rating on Allogene Therapeutics (ALLO)
Citi
$4
Buy
198.51%
Upside
Reiterated
06/02/25
Citi Keeps Their Buy Rating on Allogene Therapeutics (ALLO)
H.C. Wainwright Analyst forecast on ALLO
Robert BurnsH.C. Wainwright
H.C. Wainwright
$8
Buy
497.01%
Upside
Reiterated
06/02/25
Promising Clinical Results and Strategic Initiatives Drive Buy Rating for Allogene Therapeutics
William Blair Analyst forecast on ALLO
Sami CorwinWilliam Blair
William Blair
Buy
Reiterated
05/14/25
Positive Outlook on Allogene Therapeutics Amid ALPHA3 Trial Delays and Market Expansion Potential
Oppenheimer Analyst forecast on ALLO
Matthew BieglerOppenheimer
Oppenheimer
$10$9
Buy
571.64%
Upside
Reiterated
05/14/25
Analysts Are Bullish on Top Healthcare Stocks: Allogene Therapeutics (ALLO), Biodesix (BDSX)
Truist Financial Analyst forecast on ALLO
Asthika GoonewardeneTruist Financial
Truist Financial
$14$10
Buy
646.27%
Upside
Reiterated
05/14/25
Citizens JMP Analyst forecast on ALLO
Reni BenjaminCitizens JMP
Citizens JMP
Hold
Downgraded
05/14/25
Allogene downgraded to Market Perform from Outperform at Citizens JMPAllogene downgraded to Market Perform from Outperform at Citizens JMP
Robert W. Baird Analyst forecast on ALLO
Jack AllenRobert W. Baird
Robert W. Baird
$12$9
Buy
571.64%
Upside
Reiterated
05/14/25
Allogene Therapeutics price target lowered to $9 from $12 at BairdAllogene Therapeutics price target lowered to $9 from $12 at Baird
Jefferies Analyst forecast on ALLO
Michael YeeJefferies
Jefferies
$8
Buy
497.01%
Upside
Reiterated
05/13/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: GlaxoSmithKline (LSE: GB:GSK), Sartorius Stedim Biotech (LSE: GB:0RG8) and Allogene Therapeutics (NASDAQ: ALLO)
RBC Capital Analyst forecast on ALLO
Luca IssiRBC Capital
RBC Capital
$10
Buy
646.27%
Upside
Reiterated
05/13/25
Allogene Therapeutics (ALLO) Gets a Buy from RBC Capital
Stifel Nicolaus Analyst forecast on ALLO
Benjamin BurnettStifel Nicolaus
Stifel Nicolaus
$4
Hold
198.51%
Upside
Reiterated
03/17/25
Stifel Nicolaus Keeps Their Hold Rating on Allogene Therapeutics (ALLO)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Allogene Therapeutics

1 Month
xxx
Success Rate
6/15 ratings generated profit
40%
Average Return
-4.79%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 40.00% of your transactions generating a profit, with an average return of -4.79% per trade.
3 Months
xxx
Success Rate
8/16 ratings generated profit
50%
Average Return
-2.97%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -2.97% per trade.
1 Year
John NewmanCanaccord Genuity
Success Rate
6/23 ratings generated profit
26%
Average Return
-24.63%
reiterated a buy rating 13 days ago
Copying John Newman's trades and holding each position for 1 Year would result in 26.09% of your transactions generating a profit, with an average return of -24.63% per trade.
2 Years
xxx
Success Rate
3/14 ratings generated profit
21%
Average Return
-41.81%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 21.43% of your transactions generating a profit, with an average return of -41.81% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALLO Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
3
9
8
16
13
Buy
3
5
8
7
6
Hold
0
1
1
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
15
17
26
22
In the current month, ALLO has received 19 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. ALLO average Analyst price target in the past 3 months is 7.77.
Each month's total comprises the sum of three months' worth of ratings.

ALLO Financial Forecast

ALLO Earnings Forecast

Next quarter’s earnings estimate for ALLO is -$0.27 with a range of -$0.30 to -$0.21. The previous quarter’s EPS was -$0.28. ALLO beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.02% of the time in the same period. In the last calendar year ALLO has Outperformed its overall industry.
Next quarter’s earnings estimate for ALLO is -$0.27 with a range of -$0.30 to -$0.21. The previous quarter’s EPS was -$0.28. ALLO beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.02% of the time in the same period. In the last calendar year ALLO has Outperformed its overall industry.

ALLO Sales Forecast

Next quarter’s sales forecast for ALLO is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ALLO beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.52% of the time in the same period. In the last calendar year ALLO has Preformed in-line its overall industry.
Next quarter’s sales forecast for ALLO is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ALLO beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.52% of the time in the same period. In the last calendar year ALLO has Preformed in-line its overall industry.

ALLO Stock Forecast FAQ

What is ALLO’s average 12-month price target, according to analysts?
Based on analyst ratings, Allogene Therapeutics Inc’s 12-month average price target is 7.77.
    What is ALLO’s upside potential, based on the analysts’ average price target?
    Allogene Therapeutics Inc has 479.85% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ALLO a Buy, Sell or Hold?
          Allogene Therapeutics Inc has a consensus rating of Strong Buy which is based on 11 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Allogene Therapeutics Inc’s price target?
            The average price target for Allogene Therapeutics Inc is 7.77. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $14.00 ,the lowest forecast is $2.50. The average price target represents 479.85% Increase from the current price of $1.34.
              What do analysts say about Allogene Therapeutics Inc?
              Allogene Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of ALLO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis